Clinical Research of the Application of Bone Turnover Markers in Monitoring the Short-Term Therapeutic Efficacy of Vitamin D in Postmenopausal Osteoporotic women in Harbin, China.

Plain-language guide to PMID 32346686 (2020): randomized controlled trial of Vitamin D, K2, Magnesium and Zinc in 120 patients, osteoporosis and bone density.

Key Facts

PMID: 32346686
Journal: The journal of nutrition, health & aging
Year: 2020
Study type: Randomized Controlled Trial
Authors: Zhang Y et al. (2 authors)
DOI: 10.1007/s12603-020-1362-z

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc in the context of osteoporosis and bone density.

Combining dual-energy X-ray and bone turnover markers (BTM) to explore the VitD level in postmenopausal osteoporosis patients in Harbin and monitor its effect on the anti-osteoporosis effect of ZOL.

Why It Was Studied

Since VitD is related to the geogen, its promotion effect on zoledronate has regional specificity.

Who Took Part

According to the abstract, 120 patients were involved.

The age groups tagged for this paper are middle-aged adults, women only.

Then the experimental group was given calcitriol and calcium carbonate, and the control group was only given calcium carbonate.

How the Study Was Run

The design is described as randomized.

The patients were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

BTM were measured at baseline, 24h, 3 months and 6 months.

The researchers also measured bone mineral density (BMD) of bilateral hips (TH BMD) and lumbar spine (LS BMD) at baseline and 6 months.

What Was Measured

The subject headings attached to it are Biomarkers, Bone Density, Bone Density Conservation Agents, Bone Remodeling, China, Osteoporosis, Postmenopausal and Vitamin D.

The authors tagged it with the keywords Bone turnover markers and zoledronate.

What This Means in Plain Language

The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 120 patients in people with osteoporosis and bone density.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (The journal of nutrition, health & aging), a journal based in France.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Osteoporosis and bone density research.

Our Notes on the Compound

Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.